CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong International Arbitration Centre (the "HKIAC") issued an Order on April 5, 2024, granting the emergency injunctive relief CASI sought pending the determination of the arbitration proceeding initiated with the HKIAC in connection with the dispute (the "Arbitration Proceeding"). The emergency arbitrator's Order, among other things, prohibits Juventas from commercializing CNCT19 by itself or through another third party. The emergency arbitrator also noted in the Order that the parties shall cooperate to reach a temporary arrangement that allows them to provide CNCT19 to new patients.
2024年4月8日，CASI製藥宣佈，關於公司先前宣佈的與尤文塔斯細胞療法有限公司的爭議，香港國際仲裁中心（“HKIAC”）任命的緊急仲裁員於2024年4月5日發佈命令，批准CASI尋求的緊急禁令救濟，以待與香港國際仲裁中心啓動的與該爭議有關的仲裁程序（“仲裁程序”）作出裁決。。緊急仲裁員的命令除其他外，禁止尤文塔斯自行或通過其他第三方將 CNCT19 商業化。緊急仲裁員還在命令中指出，雙方應合作達成臨時安排，允許他們向新患者提供 CNCT19。
譯文內容由第三人軟體翻譯。